Persistence of borrelia burgdorferi in rhesus macaques following antibiotic treatment of disseminated infection

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Embers, Monica E ^a   Barthold, Stephen W ^b   Borda, Juan T ^a   Bowers, Lisa ^a   Doyle, Lara ^a   Hodzic, Emir ^b   Jacobs, Mary B ^a   Hasenkampf, Nicole R ^a   Martin, Dale S ^a   Narasimhan, Sukanya ^c   Phillippi Falkenstein, Kathrine M ^a   Purcell, Jeanette E ^a   Ratterree, Marion S ^a   Philipp, Mario T ^a  

^a TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; CEFTRIAXONE; DOXYCYCLINE; ANTIINFECTIVE AGENT; BACTERIAL DNA; PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ANTIBODY RESPONSE; ARTICLE; BACTERIUM CULTURE; BACTERIUM DETECTION; BACTERIUM IDENTIFICATION; BORRELIA BURGDORFERI; CONTROLLED STUDY; DISEASE COURSE; DNA DETERMINATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HOST PATHOGEN INTERACTION; IMMUNOFLUORESCENCE; IN VITRO STUDY; LYME DISEASE; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMERASE CHAIN REACTION; RHESUS MONKEY; RNA ANALYSIS; XENODIAGNOSIS; ANIMAL; ANTIBODY PRODUCTION; DRUG EFFECT; GENETICS; IMMUNOLOGY; INFLAMMATION; MACACA MULATTA; MICROBIOLOGY; PATHOLOGY; TREATMENT OUTCOME;

ANIMALIA; BORRELIA BURGDORFERI; IXODIDA; MACACA MULATTA; PRIMATES;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBODY FORMATION; BORRELIA BURGDORFERI; DNA, BACTERIAL; INFLAMMATION; LYME DISEASE; MACACA MULATTA; PEPTIDES; TREATMENT OUTCOME; XENODIAGNOSIS;

EID: 84855694512     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029914     Document Type: Article

References (59)

1. Steere AC, Coburn J, Glickstein L, (2004) The emergence of Lyme disease. Journal of Clinical Investigation 113: 1093-1101.
2. Wormser Gary P, Dattwyler Raymond J, Shapiro Eugene D, Halperin John J, Steere A, et al. (2006) The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America. Clinical Infectious Diseases 43: 1089-1134.
3. Asch ES, Bujak DI, Weiss M, Peterson MG, Weinstein A, (1994) Lyme disease: an infectious and postinfectious syndrome. Journal of Rheumatology 21: 454-461.
4. Shadick NA, Phillips CB, Logigian EL, Steere AC, Kaplan RF, et al. (1994) The long-term clinical outcomes of Lyme disease. A population-based retrospective cohort study. Annals of Internal Medicine 121: 560-567.
5. Steere AC, Levin RE, Molloy PJ, Kalish RA, Abraham JH 3rd, et al. (1994) Treatment of Lyme arthritis. Arthritis & Rheumatism 37: 878-888.
6. Klempner MS, Hu LT, Evans J, Schmid CH, Johnson GM, et al. (2001) Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. New England Journal of Medicine 345: 85-92.
7. Klempner MS, (2002) Controlled trials of antibiotic treatment in patients with post-treatment chronic Lyme disease. Vector Borne & Zoonotic Diseases 2: 255-263.
8. Philipp MT, Wormser GP, Marques AR, Bittker S, Martin DS, et al. (2005) A decline in C6 antibody titer occurs in successfully treated patients with culture-confirmed early localized or early disseminated Lyme Borreliosis. Clin Diagn Lab Immunol 12: 1069-1074.
9. Fleming RV, Marques AR, Klempner MS, Schmid CH, Dally LG, et al. (2004) Pre-treatment and post-treatment assessment of the C(6) test in patients with persistent symptoms and a history of Lyme borreliosis. European Journal of Clinical Microbiology & Infectious Diseases 23: 615-618.
10. Bolz DD, Weis JJ, (2004) Molecular Mimicry to Borrelia burgdorferi: Pathway to Autoimmunity? Autoimmunity 37: 387-392.
11. Philipp MT, Aydintug MK, Bohm RP Jr, Cogswell FB, Dennis VA, et al. (1993) Early and early disseminated phases of Lyme disease in the rhesus monkey: a model for infection in humans. Infection & Immunity 61: 3047-3059.
12. Roberts ED, Bohm RP Jr, Cogswell FB, Lanners HN, Lowrie RC Jr, et al. (1995) Chronic lyme disease in the rhesus monkey. Laboratory Investigation 72: 146-160.
13. Roberts ED, Bohm RP Jr, Lowrie RC Jr, Habicht G, Katona L, et al. (1998) Pathogenesis of Lyme neuroborreliosis in the rhesus monkey: the early disseminated and chronic phases of disease in the peripheral nervous system. Journal of Infectious Diseases 178: 722-732.
14. Philipp MT, Johnson BJ, (1994) Animal models of Lyme disease: pathogenesis and immunoprophylaxis. Trends in Microbiology 2: 431-437.
15. England JD, Bohm RP Jr, Roberts ED, Philipp MT, (1997) Lyme neuroborreliosis in the rhesus monkey. Seminars in Neurology 17: 53-56.
16. Pachner AR, Cadavid D, Shu G, Dail D, Pachner S, et al. (2001) Central and peripheral nervous system infection, immunity, and inflammation in the NHP model of Lyme borreliosis. Annals of Neurology 50: 330-338.
17. Cadavid D, Bai Y, Dail D, Hurd M, Narayan K, et al. (2003) Infection and Inflammation in Skeletal Muscle from Nonhuman Primates Infected with Different Genospecies of the Lyme Disease Spirochete Borrelia burgdorferi. Infect Immun 71: 7087-7098.
18. Cadavid D, O'Neill T, Schaefer H, Pachner AR, (2000) Localization of Borrelia burgdorferi in the nervous system and other organs in a nonhuman primate model of lyme disease. Laboratory Investigation 80: 1043-1054.
19. Pachner AR, (1995) Early disseminated Lyme disease: Lyme meningitis. American Journal of Medicine 98: 30S-37S; discussion 37S-43S.
20. Pachner AR, Delaney E, O'Neill T, Major E, (1995) Inoculation of nonhuman primates with the N40 strain of Borrelia burgdorferi leads to a model of Lyme neuroborreliosis faithful to the human disease. Neurology 45: 165-172.
21. Bai Y, Narayan K, Dail D, Sondey M, Hodzic E, et al. (2004) Spinal cord involvement in the nonhuman primate model of Lyme disease. Laboratory Investigation 84: 160-172.
22. Cadavid D, Bai Y, Hodzic E, Narayan K, Barthold SW, et al. (2004) Cardiac involvement in non-human primates infected with the Lyme disease spirochete Borrelia burgdorferi. Laboratory Investigation 84: 1439-1450.
23. Del Rio M, McCracken GH Jr, Nelson JD, Charne D, Shelton S, (1982) Pharmacokinetics and cerebrospinal fluid bactericidal activity of ceftriaxone in the treatment of pediatric patients with bacterial meningitis. Antimicrob Agents Chemother 22: 622-627.
24. Patel IH, Kaplan SA, (1984) Pharmacokinetic profile of ceftriaxone in man. American Journal of Medicine 77: 17-25.
25. Matsui H, Komiya M, Ikeda C, Tachibana A, (1984) Comparative pharmacokinetics of YM-13115, ceftriaxone, and ceftazidime in rats, dogs, and rhesus monkeys. Antimicrobial Agents & Chemotherapy 26: 204-207.
26. Maesen FP, Davies BI, van den Bergh JJ, (1989) Doxycycline and minocycline in the treatment of respiratory infections: a double-blind comparative clinical, microbiological and pharmacokinetic study. Journal of Antimicrobial Chemotherapy 23: 123-129.
27. Baradaran-Dilmaghani R, Stanek G, (1996) In vitro susceptibility of thirty Borrelia strains from various sources against eight antimicrobial chemotherapeutics. Infection 24: 60-63.
28. Hovind-Hougen K, (1984) Ultrastructure of spirochetes isolated from Ixodes ricinus and Ixodes dammini. Yale Journal of Biology & Medicine 57: 543-548.
29. Wormser G, Nadelman R, Dattwyler R, Dennis D, Shapiro E, et al. (2000) Practice Guidelines for the Treatment of Lyme Disease. Clinical Infectious Diseases 31: 1-14.
30. Liang FT, Steere AC, Marques AR, Johnson BJ, Miller JN, et al. (1999) Sensitive and specific serodiagnosis of Lyme disease by enzyme-linked immunosorbent assay with a peptide based on an immunodominant conserved region of Borrelia burgdorferi vlsE. Journal of Clinical Microbiology 37: 3990-3996.
31. Liang FT, Jacobs MB, Philipp MT, (2001) C-terminal invariable domain of VlsE may not serve as target for protective immune response against Borrelia burgdorferi.[erratum appears in Infect Immun 2001 Aug;69(8):5216]. Infection & Immunity 69: 1337-1343.
32. Gilmore RD Jr, Kappel KJ, Dolan MC, Burkot TR, Johnson BJ, (1996) Outer surface protein C (OspC), but not P39, is a protective immunogen against a tick-transmitted Borrelia burgdorferi challenge: evidence for a conformational protective epitope in OspC. Infection & Immunity 64: 2234-2239.
33. Auwaerter P, (2007) Point: Antibiotic Therapy Is Not the Answer for Patients with Persisting Symptoms Attributable to Lyme Disease. Clinical Infectious Diseases 45: 143-148.
34. Stricker R, (2007) Counterpoint: Long-Term Antibiotic Therapy Improves Persistent Symptoms Associated with Lyme Disease. Clinical Infectious Diseases 45: 149-157.
35. Feder HM Jr, Johnson BJ, O'Connell S, Shapiro ED, Steere AC, et al. (2007) A critical appraisal of "chronic Lyme disease". New England Journal of Medicine 357: 1422-1430.
36. Mayer L, Merz S, (2008) An appraisal of "chronic Lyme disease".[comment]. New England Journal of Medicine 358: 428; author reply 430-421.
37. Barthold SW, Hodzic E, Imai DM, Feng S, Yang X, et al. (2010) Ineffectiveness of tigecycline against persistent Borrelia burgdorferi. Antimicrobial Agents & Chemotherapy 54: 643-651.
38. Crowley H, Huber BT, (2003) Host-Adapted Borrelia burgdorferi in Mice Expresses OspA during Inflammation. Infect Immun 71: 4003-4010.
39. Narasimhan S, Caimano MJ, Liang FT, Santiago F, Laskowski M, et al. (2003) Borrelia burgdorferi transcriptome in the central nervous system of non-human primates.[erratum appears in Proc Natl Acad Sci U S A. 2004 Feb 3;101(5):1426 Note: Camaino MJ [corrected to Caimano MJ]]. Proceedings of the National Academy of Sciences of the United States of America 100: 15953-15958.
40. Kalish RA, Leong JM, Steere AC, (1993) Association of treatment-resistant chronic Lyme arthritis with HLA-DR4 and antibody reactivity to OspA and OspB of Borrelia burgdorferi. Infect Immun 61: 2774-2779.
41. YrjÄNÄInen H, HytÖNen J, Hartiala P, Oksi J, Viljanen MK, Persistence of borrelial DNA in the joints of Borrelia burgdorferi-infected mice after ceftriaxone treatment. APMIS 118: 665-673.
42. Hodzic E, Feng S, Holden K, Freet KJ, Barthold SW, (2008) Persistence of Borrelia burgdorferi following Antibiotic Treatment in Mice. Antimicrob Agents Chemother 52: 1728-1736.
43. Lewis K, (2007) Persister cells, dormancy and infectious disease. Nature Reviews Microbiology 5: 48-56.
44. Lewis K, (2010) Persister Cells. Annual Review of Microbiology 64: 357-372.
45. Straubinger RK, Summers BA, Chang YF, Appel MJ, (1997) Persistence of Borrelia burgdorferi in experimentally infected dogs after antibiotic treatment. Journal of Clinical Microbiology 35: 111-116.
46. Philipp MT, Bowers LC, Fawcett PT, Jacobs MB, Liang FT, et al. (2001) Antibody response to IR6, a conserved immunodominant region of the VlsE lipoprotein, wanes rapidly after antibiotic treatment of Borrelia burgdorferi infection in experimental animals and in humans. Journal of Infectious Diseases 184: 870-878.
47. Philipp MT, Marques AR, Fawcett PT, Dally LG, Martin DS, (2003) C6 test as an indicator of therapy outcome for patients with localized or disseminated lyme borreliosis. Journal of Clinical Microbiology 41: 4955-4960.
48. Pachner AR, Zhang WF, Schaefer H, Schaefer S, O'Neill T, (1998) Detection of active infection in nonhuman primates with Lyme neuroborreliosis: comparison of PCR, culture, and a bioassay. Journal of Clinical Microbiology 36: 3243-3247.
49. Piesman J, Hicks TC, Sinsky RJ, Obiri G, (1987) Simultaneous transmission of Borrelia burgdorferi and Babesia microti by individual nymphal Ixodes dammini ticks. Journal of Clinical Microbiology 25: 2012-2013.
50. Purser JE, Norris SJ, (2000) Correlation between plasmid content and infectivity in Borrelia burgdorferi. Proceedings of the National Academy of Sciences of the United States of America 97: 13865-13870.
51. Kelly D, Chulay JD, Mikesell P, Friedlander AM, (1992) Serum concentrations of penicillin, doxycycline, and ciprofloxacin during prolonged therapy in rhesus monkeys. J Infect Dis 166: 1184-1187.
52. Hodzic E, Feng S, Freet KJ, Borjesson DL, Barthold SW, (2002) Borrelia burgdorferi population kinetics and selected gene expression at the host-vector interface. Infection & Immunity 70: 3382-3388.
53. Embers ME, Alvarez X, Ooms T, Philipp MT, (2008) The failure of immune response evasion by linear plasmid 28-1-deficient Borrelia burgdorferi is attributable to persistent expression of an outer surface protein. Infection & Immunity 76: 3984-3991.
54. Sambrook J, Fritch EF, Maniatis T, (1989) Molecular Cloning Cold Spring Harbor, NY Cold Spring Harbor Laboratory Press pp. 9.31-9.57.
55. Liang FT, Philipp MT, (1999) Analysis of antibody response to invariable regions of VlsE, the variable surface antigen of Borrelia burgdorferi. Infection & Immunity 67: 6702-6706.
56. Liang FT, Bowers LC, Philipp MT, (2001) C-terminal invariable domain of VlsE is immunodominant but its antigenicity is scarcely conserved among strains of Lyme disease spirochetes.[erratum appears in Infect Immun 2001 Aug;69(8):5216]. Infection & Immunity 69: 3224-3231.
57. Scheiblhofer S, Weiss R, Durnberger H, Mostbock S, Breitenbach M, et al. (2003) A DNA vaccine encoding the outer surface protein C from Borrelia burgdorferi is able to induce protective immune responses. Microbes & Infection 5: 939-946.
58. Katona LI, Beck G, Habicht GS, (1992) Purification and immunological characterization of a major low-molecular-weight lipoprotein from Borrelia burgdorferi. Infection & Immunity 60: 4995-5003.
59. Jacobs MB, Norris SJ, Phillippi-Falkenstein KM, Philipp MT, (2006) Infectivity of the Highly Transformable BBE02- lp56- Mutant of Borrelia burgdorferi, the Lyme Disease Spirochete, via Ticks. Infect Immun 74: 3678-3681.